Administration of Vincristine in a Patient with Machado-Joseph Disease | Zendy

Anna Colpo | Zendy; Frederick H. Wilson | Zendy; Valentirdi | Zendy; Ephraim P. Hochberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Administration of Vincristine in a Patient with Machado-Joseph Disease

Author(s) -

Anna Colpo,

Frederick H. Wilson,

Valentirdi,

Ephraim P. Hochberg

Publication year - 2012

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000336602

Subject(s) - vinca , vincristine , vinca alkaloid , medicine , neurotoxicity , spinocerebellar ataxia , exacerbation , machado–joseph disease , chemotherapy , disease , ataxia , toxicity , pharmacology , anesthesia , psychiatry , cyclophosphamide

Chemotherapy-induced peripheral neurotoxicity is a major problem because it represents the dose-limiting side effect of a significant number of antineoplastic drugs, such as vinca alkaloids. Hereditary neuropathies usually predispose to severe vincristine neurotoxicity. Here, we report the case of a 56-year-old man with Machado-Joseph disease, also known as spinocerebellar ataxia type 3, treated with a vinca alkaloid without exacerbation of neurological symptoms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research